Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Changes in the Supervisory Board of Avontec GmbH


Martinsried (Germany), October 1st, 2007. Avontec GmbH, a Martinsried based biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory diseases today announced that with effect from September 18th, 2007, Prof. Dr. Dr. Ernst Günther Afting, former President and CEO of the GSF and also former Chairman and CEO of the Pharmaceuticals Division of the Hoechst AG group, was elected as new member and Chairman of Avontec’s Supervisory Board. In addition, Mrs. Miki Nakamori, was appointed as new member to the Board. Dr. Jörg Neermann, formerly managing partner of DVC Deutsche Venture Capital and Dr. Hongzhi Bai, VP of Medical Affairs of AnGes MG, have resigned from the company’s Supervisory Board.

Prof. Afting has more than 20 years experience within the pharmaceutical industry. From 1995 to 2005 he was President and Chief Executive Officer of the National Research Center for Environment and Health in Munich, one of the largest German government-funded research centers. Prior to that, he was President and Chief Executive Officer of Roussel Uclaf S.A. in Paris, France, and was also Chairman and CEO of the Pharmaceuticals Division of the Hoechst AG group in Frankfurt. From 1984 to 1989 he was responsible for the worldwide R & D. of the Behring Werke in Marburg, a subsidiary of the Hoechst AG, Frankfurt, where he was appointed as a board member in 1986. Prof. Afting studied Chemistry and Medicine at the Universities of Münster and Freiburg and was tenured professor and head of the Department of Protein - Chemistry in the Institute of Biochemistry at the university of Göttingen until 1984. At present Prof. Afting serves as industrial advisor to venture capital firms and is supervisory board member of several biotech companies in Europe and the USA.

Mrs. Nakamori is in charge of all licensing and business development activities of AnGes since 2001. From 1993 to 2001 Mrs. Nakamori held various positions with increasing responsibilities in the Technology & Business Development Department and the Healthcare Department at Mitsubishi Corporation. Mrs. Nakamori graduated from Kyoto University, Faculty of Agriculture in 1993.

Dr. Thomas Schulze, Chief Executive Officer of Avontec commented: “We are extremely pleased to have gained with Prof Afting an outstanding senior expert from the pharmaceutical industry in our supervisory board. Mrs. Nakamori was already instrumental in building the alliance between Avontec and our Japanese partner Anges MG. I am confident that the exceptional and wide ranging experiences of Prof. Afting and Mrs. Nakamori will be an enormous benefit to guide Avontec’s growth and development into a highly successful biopharmaceutical company. I also wish to thank Dr. Neermann and Dr. Bai for their contribution to Avontec’s past achievements. They have been a great support for us during the past years.”

Prof. Afting and Mrs. Nakamori join the members of Avontec’s Supervisory Board who are respectively Dr. Alexander Asam ( DVC Deutsche Venture Capital), Prof. Markus Hecker (University of Heidelberg), Dr. Markus Hosang (BioMedinvest AG), Stefan Keveloh (Innovationskapital Göttingen GmbH) and Dr. Liu (AnGes MG).

About Avontec

Avontec is a biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory diseases. Avontec’s clinical development programs include product candidates for several potential inflammatory indications. The lead programs, AVT-01 in asthma and AVT-02 in psoriasis, have been successfully advanced into Phase 2a clinical trials that are expected to be completed within the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec’s core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development.

Contact

Avontec GmbH, Fraunhoferstraße 15, 82152 Martinsried
Dr.


Publisher Contact Information:

AVONTEC GmbH
+49 (0) 89 8565 - 1600
t.schulze@avontec.de

Company profile of AVONTEC GmbH
Past press releases of AVONTEC GmbH.

Data


26,227
Tech investments
From our Online Data Service
16,943
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.